Clinical trial
Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a…
NCT00150384 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00150384 |
|---|---|
| Title | Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population |
| Official title | Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE) |
| Acronym | CAPABLE |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Dyslipidemia |
| Intervention type | Drug |
| Interventions | Amlodipine/Atorvastatin |
| Enrollment | 500 |
| Start date | Jul 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 27, 2021 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: